Method of treating rheumatoid arthritis with low dose type II collagen
AssigneeAutoimmune, Inc.
InventorsHoward L. Weiner, David A. Hafler, David E. Trentham
Life of this patent
Estimating the term…
Abstract
A method for suppressing autoimmune response in an afflicted joint in a human. The method involves oral administration of between about 5 and 25 .mu.g per day of type II collagen.
Claims12
A method for treating rheumatoid arthritis in humans which comprises orally administering between about 5 to 25 .mu.g per day of type II collagen to a human in need of such treatment, for a period of time sufficient to decrease at least one clinical symptom selected from the group consisting of joint tenderness, joint swelling, morning stiffness, grip strength, and 50-foot walk time.
A method of treating at least one arthritis symptom in a human in need of such treatment which comprises orally administering to said human between 5 and 25 .mu.g per day of type II collagen.
A method of treating at least one arthritis symptom in a human in need of such treatment which comprises orally administering to said human about 20 .mu.g per day of type II collagen.
A method of suppressing an autoimmune response in at least one afflicted joint in a human in need of such treatment which comprises orally administering to said human between about 5 to 25 .mu.g per day of type II collagen.
A dosage form for use in treating rheumatoid arthritis in humans comprising a pharmaceutically acceptable container holding between 5 and 25 .mu.g of type II collagen dissolved in a physiologically acceptable acid.
Dependencies are inferred from the claim text.